P3.02b-046 Afatinib Benefits Patients with Confirmed/Suspected EGFR Mutant NSCLC, Unsuitable for Chemotherapy (TIMELY Phase II Trial): Topic: EGFR Clinical
2017
-
Correction
-
Source
-
Cite
-
Save
0
References
1
Citations
NaN
KQI